


PHARMACEUTICAL 2022

Pyxis Oncology Inc. Rank 155 of 475





PHARMACEUTICAL 2022

Pyxis Oncology Inc. Rank 155 of 475

The relative strengths and weaknesses of Pyxis Oncology Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pyxis Oncology Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 239% points. The greatest weakness of Pyxis Oncology Inc. is the variable Net Income, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is -14%, being 262% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	278,673
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,708
Liabilities, Non-Current	0
Other Assets	341
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-6,258
Property and Equipment	1,007
Research and Development	51,054
Revenues	0
Selling, General and Administrative Expense	18,663

Output Variable	Value in 1000 USD
Assets	280,021
Liabilities	18,708
Expenses	69,717
Stockholders Equity	261,313
Net Income	-75,975
Comprehensive Net Income	-75,975
Economic Capital Ratio	-14%